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Soft tissue sarcomas (STS) form a heterogeneous group of
tumours both in pathological and clinical sense thus leading in
therapeutic difficulties (Dirix and Van Oosterom, 1995).
Favourable outcome of the disease not only requires early diag-
nosis but also rather aggressive first line treatment combining
extensive surgery, radiotherapy and in selected cases also
chemotherapy. Currently, prognosis estimations are based on the
histological grade, size and the depth of the tumour (Collin et al,
1987; Rööser et al, 1987; Alvegård et al, 1989). Meanwhile, new
prognostic factors are actively being searched for, mainly in the
field of tumour biology. Cell proliferation markers such as flow
cytometrically defined S-phase fraction (SPF) describing the
proportion of dividing cells (Huuhtanen et al, 1996; Collin et al,
1997) as well as the expression of cell cycle antigens Ki-67 and
PCNA (Choong at al, 1995) seem to have prognostic value in STS.
Overexpression of certain inactive mutated forms of the tumour
suppressor gene p53 has also been shown to predict unfavourable
outcome in STS (Taubert et al, 1996). However, further studies are
needed to find out the most useful prognostic parameters for the
future clinical practice. 
Cell–cell and cell–matrix interactions are essential for normal
growth and differentiation of cells as well as for tumour develop-
ment and invasion. A variety of adhesion molecules participate in
these interactions and CD44 is one of them. CD44 comprises a
family of hyaluronic acid binding cell surface glycoproteins
encoded by a cDNA with 20 exons. 10 of them, coding for the
extracellular domains, can be alternatively spliced thereby
producing a large number of variant molecules (CD44v). Further
diversity can be accomplished by post-translational modifications,
mainly glycosylation. Both alternative splicing and glycosylation
influence the function of a particular CD44 isoform (reviewed
in Naor et al, 1997) by affecting the ligand-binding properties of
the molecule. Overall, CD44 molecules are involved in various
physiological functions. They participate in lymphocyte homing
(Jalkanen et al, 1986) and mediate cell adhesion to several extra-
cellular matrix components (Miyake et al, 1990a). They have a
role in lymphohaematopoiesis (Miyake et al, 1990b) in homotypic
cell adhesion (Belitsos et al, 1990), in T-cell activation and adhe-
sion (Denning et al, 1984), in cytokine release (Webb et al, 1990)
and lateral movement of cells (Jacobson et al, 1994). 
The standard form of CD44 is widely expressed in several tissue
types while distribution of the variant forms is mainly restricted to
different epithelia (Mackay et al, 1994). The significance of
several CD44 isoforms, including CD44v6, in the biology of
malignant diseases has been shown in a number of animal and
human studies (Günthert et al, 1991; Naor et al, 1997). Neo-
expression or upregulation of a certain CD44 splice variant has
been associated with poor survival rate in many malignant
diseases, whereas in others unfavourable outcome occurs when the
tumour looses its CD44 expression (Naor et al, 1997). 
There is not much data of adhesion molecule expression and
their significance in STS as a group. We chose to retrospectively
investigate the expression of CD44 as such and the expression of
CD44v6 in STS, since many times they have been shown to have a
role in tumour biology and to reflect the clinical behaviour of a
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malignant disease. A standard immunohistochemical analysis of
the expression of these molecules was performed to visualize their
distribution in primary soft tissue sarcomas. The expression levels
were correlated with several widely used clinicopathological para-
meters and the prognosis. 
MATERIALS AND METHODS 
Patients 
Originally 155 adult patients with a limb or superficial trunk
tumour treated at the Helsinki University Central Hospital
(HUCH) in January 1987–May 1993 were included in this study.
In each case the tumour diagnosis was based on histopathological
examination. Well-preserved paraffin blocks of the primary
tumour were available in 133 cases and the samples were all taken
before the beginning of any treatment. The median age of the
patients was 54 years (range from 18 to 89 years) at the time of
diagnosis. The female to male ratio was 5:4 (74 and 59 patients,
respectively). The treatment of these patients was based on the
guidelines set by the Helsinki STS group. Surgery alone with wide
or compartmental margin as well as surgery with marginal margin
combined with postoperative radiotherapy were considered as
adequate treatment protocols for the primary neoplastic lesion
based on the results from a previous study (Wiklund et al, 1996).
Three patients with extraskeletal Ewing’s sarcoma received
preoperative chemotherapy as part of primary treatment and
another three patients had chemotherapy after the operation. All
the patients were regularly followed-up at the outpatient depart-
ment. The median follow-up time of living patients was 68 months
(range from 9 to 453 months). During the follow-up period 43
patients (32%) developed a local tumour recurrence, and 50
patients (38%) received metastases. 53 patients (40%) have died
since, 37 (28%) of whom from STS. Detailed pre-treatment
characteristics are presented in Table 1. 
The Helsinki STS team is part of the larger Scandinavian
Sarcoma Group that applies a four-grade grading system for histo-
logical malignancy. The grading is based on histology and
histopathological parameters such as necrosis, vascular invasion,
cellularity, mitotic activity and nuclear pleomorphism. All the
histological diagnoses were reconfirmed by a pathologist special-
ized in sarcomas (PL). Measurements of cell proliferation rate as
S-phase fraction determined by DNA flow cytometry, and the
nuclear antigen Ki-67 expression detected by immunohistochem-
istry were performed earlier (Huuhtanen et al, 1996; Huuhtanen et
al, 1999). The median SPF for all the tumours was 7.3% (range
from 0.0 to 38.2%), for diploid tumours it was 4.05% (range from
0.80 to 21.9%) and for non-diploid tumours it was 12.75% (range
from 0 to 38.2%), respectively (Huuhtanen et al, 1996). 
Monoclonal antibodies 
Monoclonal antibody (mAb) Hermes-3 recognizes an epitope in
the constant part of CD44 (Jalkanen et al, 1987). mAb 20E6, rat
IgG1 against human CD44v6, was produced by immunizing
Spraque-Dawley rats with purified CDv6-v10 antigen in incom-
plete Freund’s adjuvant by an injection into the footpads 3 times at
1-week intervals. Popliteal lymph node lymphocytes were isolated
and fused with NS-1 myeloma cells according to a standard proce-
dure. The positive hybridoma, 20E6, was subcloned twice. 
Namalwa cells transfected either with CD44v6-10, CD44v7–10
or with the standard CD44 only were used for testing the
hybridoma supernatants by a single-colour indirect immunofluo-
rescence staining. Shortly, stable CD44 transfectants were incu-
bated with hybridoma supernatants for 20 minutes, followed by
secondary antibody that was a FITC-conjugated goat antirat IgG
(Sigma). Analyses were performed by FACScan cytometer
(Becton Dickinson, Mountain View, CA). mAb 20E6 was shown
to recognize CD44 isoform containing the exon v6 domain (Figure
1). A more detailed description of the preparation of the Namalwa
transfectants is presented elsewhere (Aho et al, 1997). Tonsil
sections were also stained immunohistochemically with 20E6 and
it was found to function well on both frozen and paraffin-
embedded samples. 
As a negative control we used 3G6, a mAb against avian T-cells.
All these antibodies were used either as supernatants or ammo-
nium sulphate precipitated concentrates. To stain the epithelial
components of the synovial sarcomas we used a commercial anti-
cytokeratin mAb AE1/AE3 (Boehringer-Mannheim, Mannheim,
Germany). 
Immunohistochemical techniques 
A standard immunoperoxidase staining procedure was carried 
out to detect the expression of the molecules studied. Briefly, 
5 mm sections were cut and fixed on glass by incubating at 
37˚C overnight. Dewaxing was done in xylene. To rehydrate the
Table 1 Pretreatment characteristics 
Parameter n % 
Size
< 5 cm 56 42 
³ 5 cm 74 56 
Unknown 3 2 
Grade
I8 6  
II 24 19 
III 50 40 
IV 43 35 
Location
Trunk 32 21 
Limb 123 79 
Site
Only cutaneous/subcutaneous 90 58 
Deep 63 41 
Unknown 2 1 
Ploidy
Diploid 68 51 
Aneuploid 65 49 
Histological type
Malignant fibrous histiocytoma 37 28 
Liposarcoma 15 12 
Leiomyosarcoma 14 12 
Synovial sarcoma 8 6 
Fibrosarcoma 8 6 
Dermatofibrosarcoma 8 6 
Extraskeletal Ewing’s sarcoma 7 5 
Malignant schwannoma 4 3 
Extraskeletal osteosarcoma 2 1 
Epitheloid sarcoma 2 1 
Angiosarcoma 2 1 
Other sarcomasa 75  
Unclassified sarcoma 19 14 
aOther sarcomas: myxofibrosarcoma, extraskeletal myxoid chondrosarcoma,
clear cell sarcoma, rhabdomyosarcoma, alveolar rhabdomyosarcoma,
stromal sarcoma and malignant hemangiopericytoma. 246 S Maula et al
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tissues, the sections were run through a series of decreasingly graded
ethanol baths. Immunoreactivity was triggered by a pre-treatment in
acidic conditions (pH = 6.0) in a microwave oven.
The Vectastain ABC kit (Vector laboratories, Inc, Burlingame,
California) was used for the actual staining. Non-specific binding
was blocked by normal horse serum. The primary antibodies were
diluted in TBS (tris-buffered saline) containing 1% bovine serum
albumin (BSA). Hermes-3 and 3G6 were supernatants from serum-
free cultures and were used as 1:80 and 1:30 dilutions, respectively.
20E6 was an antibody concentrate used as a 10 mg ml–1 dilution. The
incubation with the primary antibody was done overnight at+4˚C.
Biotinylated monoclonal IgG was used as the second stage reagent.
The signal amplification was obtained by incubating the sections
with avidin and biotinylated horseradish peroxidase for 30 minutes
at room temperature. All of the incubations with antibodies and
other reagents took place in humidified chambers at room tempera-
ture unless otherwise mentioned. Each of the above steps was
followed by 3 washes in TBS (5 minutes each). 3,3-diaminobenzi-
dine in TBS containing 0.03% H2O2 was used as a substrate for the
peroxidase-mediated reaction, and Mayer’s haematoxylin was used
for the background staining. Finally, the sections were dehydrated in
an increasingly graded series of ethanol, cleared in xylene and
permanently mounted in DePex (BDH Limited, Poole, Dorset, UK).
The antibody (Hermes-3, 20E6, 3G6) staining intensity was scored
on a visual scale as – meaning no staining, + for weak staining, ++
corresponding to moderate staining and +++ for strong antibody
binding. The staining intensities of lymphocytes as well as of
epithelia were used as internal controls when determining the CD44
expression levels. In CD44v6 stainings epithelial staining intensity
functioned as an internal control. The expression intensities were
assessed by 3 independent experienced readers (SM, RR, PL)
without the knowledge of any clinical data. Normal non-malignant
tissues (n = 9) representing the same tissue types from which the
STS included in this study came from were also stained with the
same antibodies and the general expression pattern of CD44 and
CD44v6 was compared between normal and malignant tissues. 
Statistical analysis 
The SPSS Macintosh computer program was used for the statistical
analyses. The testing of the association between CD44/CD44v6
expression and proliferation, grade and size was done with
Pearson’s correlation coefficient test for continuous data and the
Chi-square test for trends for categorial variables. The association
between CD44/CD44v6 expression and local recurrence, distant
recurrence and disease-specific survival was done with the Cox
regression analysis with CD44/CD44v6 expression coded from 0
(negative) to 3 (+++). Risk ratios for local recurrence, distant recur-
rence and death were estimated from the same Cox model.
Dermatofibrosarcomas (DFSP, n = 8) were excluded from the
overall survival and metastasis-free survival analyses as it is well
known that these malignancies do not form distant recurrences. 
RESULTS 
CD44 expression 
127 (95%) of the primary STS expressed CD44 and CD44v6 was
detected in 76 (57%) of the neoplasms. Only 5 tumours (4%)
entirely lacked CD44 expression. 45% of the tumours expressed
CD44 as strongly as the normal epithelium (+++), 46% moderately
(++) and the rest 9% revealed weak positivity (+) or no expression
(–). In general, CD44v6 expression was relatively weak compared
to that of all CD44; none of the samples stained strongly (+++)
with the mAb 20E6, 9% showed moderate (++) staining, 50%
stained faintly (+) and 43% were completely negative. The expres-
sion of both, CD44 in general as well as that of CD44v6
was mainly restricted to the cell membrane. CD44 and CD44v6
CD44s
CD44v6–v10
CD44v7–v10
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104
Hermes-3 20E6 neg. co Construct
Figure 1 Specificity of mAb 20E6. Hermes-3 recognizes all CD44 isoforms. 20E6 recognizes the CD44 form containing variant exons v6–v10 but not the
CD44v7–v10 form nor the standard CD44 molecule. Thus, it appears to specifically recognize an epitope encoded by the variant exon v6. 3G6 was used as a
negative control The role of CD44 and CD44v6 in adult STS 247
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expression patterns are shown in detail by each STS group in Table 2.
Examples of different expression levels are shown in Figure 2. 
Stainings of mesenchymal tissue samples obtained from STS-
free patients revealed moderate CD44 expression, the only excep-
tion being striated muscle where no CD44 was found. Stronger
staining was seen in the endothelium of capillaries and larger
blood vessels where the CD44 expression level resembling that of
circulating blood lymphocytes. All of these non-malignant
mesenchymal tissue samples revealed no expression or only weak
expression (+) of the variant molecule CD44v6. 
Synovial sarcomas consist of two distinct cell types, epithelial
and spindle cells. Epithelial cells are known to contain cytokeratin
and therefore we confirmed the location of the cells of epithelial
origin in our synovial sarcoma material by performing an 
anti-cytokeratin staining with the monoclonal antibody AE1/AE3.
We also found that CD44 was predominantly located in the epithe-
lial components of these neoplasms when the cytokeratin staining
was compared to the CD44 staining. 
Correlations between the expression and the
clinicopathological parameters 
Strong CD44 expression was found to be associated with low
histological grade in the primary STS (P = 0.04); 97% (31/32) of
the low-grade (grades I and II) and 88% (82/93) of the high-grade
(grades III and IV) tumours expressed CD44 moderately or
strongly (Table 3). In contrast, CD44v6 expression did not corre-
late with the tumour grade (P > 0.1). Expression of CD44, but not
d
f
a b
e
c
Figure 2 Examples of the expression of CD44 (a, b, c) and CD44v6 (d, e, f) in human soft tissue sarcomas, a, Strong expression (+++) of CD44 in a MFH
tumour. b, Moderate expression (++) of CD44 seen in another malignant fibrous histiocytoma. c, This is an unclassified sarcoma having no CD44 expression (–)
in the tumour cells. d, Moderate (++) expression of CD44v6 in a MFH. e, Weak (+) and mainly cytoplasmic variant 6 expression was found in another MFH
tumour. f, A CD44v6-negative (–) dermatofibrosarcoma. ´ 200 that of the variant form v6, was also associated with the tumour
size so that strong expression correlated with small size (P = 0.02
and P = 0.23). No significant statistical correlation was found
between either CD44 or CD44v6 expression and the age at
diagnosis, sex or tumour ploidy (P > 0.1 for all the above compar-
isons). 
In the patient material as a whole, there was no overall correla-
tion between CD44 expression and tumour proliferation rate
assessed by S-phase fraction or Ki-67 expression (P > 0.1 for all
comparisons). In the group of diploid tumours (n = 68), however, a
significant inverse correlation between CD44 expression and the
SPF was found (r = –0.40, P = 0.001). A trend towards a correla-
tion between CD44 and proliferation assessed by Ki-67 was also
seen in diploid tumours (r = –0.23, P = 0.09). No association could
be found between the CD44v6 expression and the level of SPF or
Ki-67 in diploid neoplasms (P > 0.1 for both comparisons). Within
the group of aneuploid tumours neither CD44v6 nor CD44 gener-
ally was significantly correlated with SPF or Ki-67 (SPF: P = 0.72
for CD44 and P = 0.45 for CD44v6; Ki-67: P = 0.78 for CD44 and
P = 0.57 for CD44v6). 
Local recurrence 
During the follow-up period 43 patients were seen to develop a
local relapse. The factor most significantly associated with local
recurrence was the adequacy of local treatment (P = 0.0001), 63%
(n = 84) of the patients were considered as having received
adequate local tumour treatment. Despite aggressive first line
treatment 16 of these patients (19%) later had a local relapse.
However, in the group of inadequately treated patients as many as
27 (55%) out of all 49 patients were later seen to develop a local
recurrence. No significant correlation was seen when the incidence
of local recurrences was compared with sex, histological tumour
grade, size or SPF (P > 0.1 for all comparisons). 
Local relapses were seen more often in patients whose primary
STS tumour expressed high levels of CD44 (Figure 3A, P = 0.01)
and also in patients having a STS with a high CD44v6 content
(Figure 3B, P = 0.05). In the group of adequately treated patients
The role of CD44 and CD44v6 in adult STS 249
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Figure 4 Disease specific survival of 125 adult patients with a STS by
CD44v6 expression
Table 3 CD44 expression and histological grade in 125 adult primary soft
tissue sarcoma tumours 
CD44 staining intensity 
Grade n – + ++ +++ 
I 8 0 (0%) 0 (0%) 5 (62%) 3 (38%) 
II 24 1 (4%) 0 (0%) 11 (46%) 12 (50%) 
III 50 0 (0%) 2 (4%) 24 (48%) 24 (48%) 
IV 43 5 (12%) 4 (9%) 19 (44%) 15 (35%) 
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Figure 3 (A) Local control in 133 adult patients with a STS by CD44
expression.(B) Local control in 133 adult patients with a STS by CD44v6
expression. (C) Local control in adequately treated patients with a STS 
(n = 89) by CD44 expression 
Table 4 Univariate and multivariate analysis for local recurrence 
Univariate analysis Multivariate analysis 
Factor P Relative risk P Relative risk 
(95% CI)  (95% CI)
CD44 0.01 2.04 (1.2–3.6) 0.12 1.5 (0.89–2.66) 
CD44v6 0.05 1.7 (1.0–2.8) 0.13 1.5 (0.89–2.41) 
Adequate local  0.0001 0.28 (0.15–0.53)  0.0009 0.33 (0.17–0.63) 
treatment250 S Maula et al
British Journal of Cancer (2001) 84(2), 244–252 © 2001 Cancer Research Campaign
there was a trend towards a higher local recurrence rate in tumours
with high CD44 expression (risk ratio 2.2, P = 0.09) (Figure 3C)
but no significant association between the CD44 variant v6
expression and local recurrence (risk ratio 1.78, P = 0.65). Within
the patients having received non-optimal local treatment, on the
other hand, a trend towards an association between the expression
of CD44v6 and local recurrence was seen (risk ratio 1.78, P =
0.06) whereas no correlation was found between CD44 expression
and local control rate (risk ratio 1.33, P = 0.36). In Table 4 we
present the relative risks and 95% confidence intervals (95% CI)
as well as P values for the 3 factors, adequate local treatment,
CD44 and CD44v6 expression in uni- and multivariate analyses
concerning local recurrence. 
Survival 
In univariate analysis low CD44v6 content of the primary STS
tumour was found to predict poor prognosis (P = 0.02) (Figure 4).
Adequate treatment, histological tumour grade and size of the
neoplasm were other factors also associated with the survival and
thus included in the multivariate analysis where they all seemed to
be more independent prognostic indicators than CD44v6 expres-
sion. Results of the uni- and the multivariate analyses are
presented in Table 5. The expression of CD44 seen in the primary
STS tumour did not show any correlation with the survival 
(P > 0.1). Neither of the studied CD44 isoforms had any predictive
value for metastasis-free survival (P > 0.1 for both analyses). 
DISCUSSION 
The most interesting finding in this work was the more frequent
incidence of local relapses in those STS patients whose tumour
expressed a significant amount of CD44 or even more specifically
the variant form containing the exon v6 protein domain. The risk
was two-fold when compared between two expression level
groups. Moreover, none of the strongly CD44-positive tumours
that had been treated adequately according to common standards
had metastasized. This finding may suggest that CD44 could have
an anchoring role by tightly binding the primary tumour cells to
the original tumour site. Tumour cells strongly expressing CD44
may have wider contacts with the surrounding cells, the ECM and
growth-regulating cytokines. They could thereby possess better
proliferation capacity and thus enhance tumour formation locally.
On the other hand, as the malignant cells are tightly bound
together as well as to the surrounding tissue they are less likely to
detach from the tumour mass to form distant recurrences. This
kind of behaviour of the CD44 molecule could also explain why,
despite fairly benign grading and adequate primary treatment,
certain tumours tend to form local recurrences. 
In the present study, almost all primary soft tissue sarcoma
tumours expressed CD44 molecules on their cell surfaces, at least
to some extent, whereas the splice variant CD44v6 was found only
in half of them. Fast proliferating tumours expressed only
marginal levels of CD44 which also is consistent with the hypoth-
esis of the CD44-molecule participating in local tumour control.
Furthermore, high CD44 expression was associated with a low
histological grade and small tumour size. Only 5 tumours were
completely CD44-negative. All but one of them were extraskeletal
Ewing’s sarcomas. Ewing’s sarcomas are primitive tumours that
supposedly arise from early neuroectodermal cells. Picker et al
have earlier shown that neurons generated from the same origin
are CD44-negative, whereas glial cells expressed variable levels
of CD44 (Picker et al, 1989). Our data concerning CD44 expres-
sion in Ewing’s sarcomas, when the tumour origin is also consid-
ered, is thus congruent with these previous findings. 
The structural details of CD44 are relatively well known but the
functional relevance of the different CD44 isoforms is still poorly
understood. The adhesive properties of CD44 seem to vary
between different cell types and are affected by the activation
status of the CD44 expressing cell. Despite controversial results,
different CD44 isoforms seem to have differential ligand binding
properties (Jackson et al, 1995). CD44, and especially its splice
variants, have been shown to have a critical role in embryogenesis
directing growth and differentiation of developing cells (Ruiz et al,
1995) and this physiological function is generally thought to
closely resemble malignant growth. Certain cytokines are known
to modify the function of this adhesion molecule group, perhaps
leading to changes in the cytoskeletal organization of a cell and in
cell motility which, again, are also necessary features for metasta-
sizing tumour cells. 
CD44v6 was earlier thought to be an adhesion molecule univers-
ally related to metastasis formation but the more different kinds of
tumour groups have been studied the more complicated its role has
become. A number of studies emphasizing the essential role of
CD44v6 in tumour cell spreading have been published (Koopman
et al, 1993; Herrlich et al, 1995; Kainz et al, 1995; Mulder et al,
1995), however, it has become obvious that CD44v6 behaves
differently in different neoplastic groups; depending on the tumour
type both increases and decreases of the cell surface CD44v6
expression have been correlated with the disease-specific outcome
(Naor et al, 1997). Poor survival related with low CD44v6 expres-
sion has been mainly reported in squamocellular carcinomas and
in transitional cell carcinomas of the bladder (Hong et al, 1995;
Hudson et al, 1996; Ross et al, 1996; Seelentag et al, 1996; Sugino
et al, 1996). Similarly, in the case of STS, lack rather than excess
of CD44v6 was correlated with poor survival and hence CD44v6
could be suitable as a useful prognostic factor in these malignan-
cies. Perhaps loose interaction with the surrounding cells and the
extracellular matrix enhance tumour cell detachment from their
environment, tumour cell migration and haematogenic metastasis
formation. This hypothesis is supported not only by our results
concerning local recurrences and the survival, but also by the data
presented by Soukka et al where they showed with squamocellular
carcinomas that diminished CD44v6-expression was associated
with poorly differentiated rapidly growing neoplasms (Soukka 
et al, 1997). In a very recent report by Ishida, a decreased CD44v6
expression was associated with a higher probability of invasion
but not of metastasis formation in colorectal adenocarcinomas
further supporting our finding (Ishida, 2000). 
Table 5 Univariate and multivariate analysis for disease specific survival 
Univariate analysis Multivariate analysis 
Factor P Relative risk P Relative risk 
(95% CI)  (95% CI)
CD44 0.39 0.85 (0.6–1.2) – – 
CD44v6 0.03 0.57 (0.3–1.0) 0.13 0.65 (0.4–1.1) 
Grade 0.02 1.86 (1.2–2.8) 0.03 1.58 (1.0–2.4) 
Size <0.00005 1.09 (1.0–1.1) 0.0003 1.08 (1.0–1.1) 
Adequate local 0.004 0.41 (0.2–0.8) 0.0001 0.28 (0.1–0.5)
treatmentRecently, Kahara et al published a small descriptive study on
CD44 expression in 47 STS. They found that both CD44v6 and
CD44v9 were the predominately expressed CD44 variants in STS
validating our study. Despite the restricted patient material they
found a correlation between CD44v6 expression and metastasis-
free survival (Kahara et al, 2000). That could not be found in our
study, perhaps because of larger histological heterogeneity in our
tumour material. The same reason may also, at least partially,
explain why we found a correlation between low CD44v6 expres-
sion and the survival in univariate analysis but failed to confirm
the result in multivariate analysis. 
In conclusion, this was the first time the expression and clinical
importance of CD44, an adhesion molecule family often linked
with tumour prognosis, was studied in STS. We found both the
standard and the variant form v6 of CD44 molecule commonly
expressed in STS. The expression of CD44 was related to the incid-
ence of local recurrences as well as to tumour size and grade.
Expression of CD44v6 was also linked to the later occurrence of
local relapses. Moreover, low expression of CD44v6 predicted
poor disease-specific survival. These findings, if confirmed, could
be of great clinical relevance as the tumours with a high CD44
expression were associated with a higher risk for local failure and
a lower risk for distant recurrence. They would thus be ideal candi-
dates for determining the patients benefiting from intensified local
treatment. 
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